Symbol="INO"
AssetType="Common Stock"
Name="Inovio Pharmaceuticals Inc"
Description="Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases. "
CIK="1055726"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="SURGICAL & MEDICAL INSTRUMENTS & APPARATUS"
Address="6769 MESA RIDGE RD., SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="118221000"
EBITDA="-169114496"
PERatio="None"
PEGRatio="0"
BookValue="0.632"
DividendPerShare="0"
DividendYield="0"
EPS="-0.62"
RevenuePerShareTTM="0.038"
ProfitMargin="0"
OperatingMarginTTM="-17.95"
ReturnOnAssetsTTM="-0.312"
ReturnOnEquityTTM="-0.721"
RevenueTTM="9619700"
GrossProfitTTM="-177388235"
DilutedEPSTTM="-0.62"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.712"
AnalystTargetPrice="1.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="40.0"
PriceToBookRatio="1.721"
EVToRevenue="19.1"
EVToEBITDA="-0.649"
Beta="0.986"
num_52WeekHigh="2.61"
num_52WeekLow="0.38"
num_50DayMovingAverage="0.487"
num_200DayMovingAverage="1.14"
SharesOutstanding="268075000"
DividendDate="None"
ExDividendDate="None"
symbol="INO"
open="0.44"
high="0.46"
low="0.42"
price="0.44"
volume="2737460.00"
latest_trading_day="2023-08-21"
previous_close="0.44"
change="-0.00"
change_percent="-0.1359%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="7628285"
Change_recent_avg="0.01"
Delta_recent_avg="0.05"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.94"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="127"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0049.jpeg"
image_negative_thumbnail_id_2="491"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0114.jpeg"
image_neutral_thumbnail_id_1="538"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0061.jpeg"
image_neutral_thumbnail_id_2="542"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0057.jpeg"
image_positive_thumbnail_id_1="970"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0132.jpeg"
image_positive_thumbnail_id_2="1006"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0168.jpeg"
image_professor_thumbnail_id_1="1194"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
